UNBX — Unity Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $1.03m
- -$15.90m
Annual income statement for Unity Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 4.78 | 0.236 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 93.9 | 61.2 | 57.6 | 45.2 | 31.2 |
| Operating Profit | -93.9 | -56.5 | -57.4 | -45.2 | -31.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -93.8 | -60.7 | -44.5 | -39.9 | -26 |
| Net Income After Taxes | -93.8 | -60.7 | -44.5 | -39.9 | -26 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -93.8 | -60.7 | -44.5 | -39.9 | -26 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -93.8 | -60.7 | -44.5 | -39.9 | -26 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -17.9 | -10.9 | -4.5 | -2.24 | -1.38 |